Exicure (FRA:2H0) Cyclically Adjusted FCF per Share: €-34.43 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2H0 Exicure Inc FRA:2H0
32 GF Score
Price €0.88
! 3 Warning Signs
View Full Analysis

What is Exicure Cyclically Adjusted FCF per Share?

Exicure FRA:2H0 +2.33% 32 Cyclically Adjusted FCF per Share is €-34.43 as of Jun. 2026. GuruFocus rates FRA:2H0 with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Exicure's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.121. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-34.43 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-09-02), Exicure's current stock price is €0.88. Exicure's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-34.43. Exicure's Cyclically Adjusted Price-to-FCF of today is .


Exicure  (FRA:2H0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Exicure Cyclically Adjusted FCF per Share Related Terms


Exicure Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Exicure's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exicure Cyclically Adjusted FCF per Share Chart

Exicure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Exicure Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -34.43

FRA:2H0 vs HEPA, SNGX, ALZN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Exicure's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exicure Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exicure's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Exicure's Cyclically Adjusted Price-to-FCF falls into.


FRA:2H0
32GF Score
Exicure Inc FRA:2H0
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exicure Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Exicure's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.121/333.9520*333.9520
=-0.121

Current CPI (Jun. 2026) = 333.9520.

Exicure Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.000 241.428 0.000
201612 19.996 241.432 27.659
201703 -25.745 243.801 -35.265
201706 -12.179 244.955 -16.604
201709 -13.825 246.819 -18.706
201712 -17.806 246.524 -24.121
201803 -14.331 249.554 -19.178
201806 -15.247 251.989 -20.206
201809 -12.971 252.439 -17.159
201812 -17.706 251.233 -23.536
201903 -12.020 254.202 -15.791
201906 -15.064 256.143 -19.640
201909 -11.411 256.759 -14.842
201912 25.757 256.974 33.473
202003 -12.966 258.115 -16.776
202006 -20.460 257.797 -26.504
202009 -12.730 260.280 -16.333
202012 -16.813 260.474 -21.556
202103 -21.551 264.877 -27.171
202106 -16.140 271.696 -19.838
202109 6.957 274.310 8.470
202112 -20.755 278.802 -24.861
202203 -14.376 287.504 -16.699
202206 -9.536 296.311 -10.747
202209 -6.660 296.808 -7.493
202212 -6.910 296.797 -7.775
202303 -2.463 301.836 -2.725
202306 -2.634 305.109 -2.883
202309 -0.765 307.789 -0.830
202312 -0.432 306.746 -0.470
202403 -0.239 312.332 -0.256
202406 -0.626 314.175 -0.665
202409 -0.213 315.301 -0.226
202412 -0.310 315.605 -0.328
202503 -0.239 319.799 -0.250
202506 -0.313 322.561 -0.324
202509 -0.475 324.800 -0.488
202512 -0.154 324.054 -0.159
202603 -0.155 330.213 -0.157
202606 -0.121 333.952 -0.121

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-34.43 mean?
Exicure (FRA:2H0) has a Cyclically Adjusted FCF per Share of €-34.43 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Exicure and its competitors.
Is Exicure's Cyclically Adjusted FCF per Share too high?
Exicure's current Cyclically Adjusted FCF per Share is €-34.43. Overall, Exicure has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Exicure's Cyclically Adjusted FCF per Share compare to HEPA and SNGX?
Exicure's Cyclically Adjusted FCF per Share of €-34.43 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Exicure and its competitors. Exicure's current Cyclically Adjusted FCF per Share is €-34.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exicure stock overvalued right now?
Exicure (FRA:2H0) has a current Cyclically Adjusted FCF per Share of €-34.43. The current Cyclically Adjusted FCF per Share is €-34.43. Exicure's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Exicure (FRA:2H0), the current Cyclically Adjusted FCF per Share is €-34.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exicure Business Description

Other Exchanges XCUR:USA2H0:Germany
Address 400 Seaport Court, Suite 102, Redwood City, CA, USA, 94063
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
32GF Score

Get the complete analysis for FRA:2H0

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.88
Price